Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus PATHILON.
CANTIL vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic